Controlled Crystallization of the Lipophilic Drug Fenofibrate During Freeze-Drying: Elucidation of the Mechanism by In-Line Raman Spectroscopy by de Waard, Hans et al.
Research Article
Controlled Crystallization of the Lipophilic Drug Fenofibrate
During Freeze-Drying: Elucidation of the Mechanism
by In-Line Raman Spectroscopy
Hans de Waard,
1,4 Thomas De Beer,
2 Wouter L. J. Hinrichs,
1 Chris Vervaet,
3
Jean-Paul Remon,
3 and Henderik W. Frijlink
1
Received 29 March 2010; accepted 9 June 2010; published online 13 July 2010
Abstract. We developed a novel process, “controlled crystallization during freeze-drying” to produce
drug nanocrystals of poorly water-soluble drugs. This process involves freeze-drying at a relatively high
temperature of a drug and a matrix material from a mixture of tertiary butyl alcohol and water, resulting
in drug nanocrystals incorporated in a matrix. The aim of this study was to elucidate the mechanisms that
determine the size of the drug crystals. Fenoﬁbrate was used as a model lipophilic drug. To monitor the
crystallization during freeze-drying, a Raman probe was placed just above the sample in the freeze-dryer.
These in-line Raman spectroscopy measurements clearly revealed when the different components
crystallized during freeze-drying. The solvents crystallized only during the freezing step, while the solutes
only crystallized after the temperature was increased, but before drying started. Although the solutes
crystallized only after the freezing step, both the freezing rate and the shelf temperature were critical
parameters that determined the ﬁnal crystal size. At a higher freezing rate, smaller interstitial spaces
containing the freeze-concentrated fraction were formed, resulting in smaller drug crystals (based on
dissolution data). On the other hand, when the solutes crystallized at a lower shelf temperature, the
degree of supersaturation is higher, resulting in a higher nucleation rate and consequently more and
therefore smaller crystals. In conclusion, for the model drug fenoﬁbrate, a high freezing rate and a
relatively low crystallization temperature resulted in the smallest crystals and therefore the highest
dissolution rate.
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INTRODUCTION
Many newly developed drugs are categorized as class II
drugs according to the Biopharmaceutics Classiﬁcation System
(1). These drugs have a low solubility in water, but once
dissolved, they are easily absorbed over the gastro-intestinal
membrane (2,3). For many of these drugs, the dissolution rate is
the rate-limiting step for absorption. Therefore, the bioavail-
ability can be improved by increasing the dissolution rate (4).
Onestrategyforincreasingthedissolutionrateistheapplication
of drug nanocrystals (5–8). The dissolution rate of nanocrystals
is increased by their increased surface area (Noyes–Whitney
equation) (9),the decreased thicknessof thediffusionboundary
layer (10), and the increased saturation concentration around
the small particles (Kelvin’sl a w )( 11).
Current methods to prepare drug nanocrystals can be
divided into top-down and bottom-up methods. Most currently
used top-down methods are high-pressure homogenization (12)
and wet-ball milling (13). Disadvantages of these methods
include the use of surfactants, the difﬁculty of achieving a
uniformsize distribution,lowyields,andpossiblecontamination
from grinding media (14–16). For currently used bottom-up
methods, disadvantages includethe use of toxicsolvents andthe
difﬁculty of adequately controlling the particle size (16,17).
To overcome these disadvantages, we developed a novel
bottom-up process to produce drug nanocrystals: controlled
crystallization during freeze-drying (CCDF) (18). Brieﬂy, this
method consisted of the following steps. Firstly, two solutions
are prepared: one is a solution of the poorly water-soluble drug
in tertiary butyl alcohol (TBA) and the other is a solution of a
matrix material in water. These solutions are mixed, frozen, and
then freeze-dried. Freeze-drying is performed at a relatively
high temperature to allow both the drug and the matrix to
crystallize. By using this process, nanocrystalline dispersions
with improved dissolution behavior were obtained.
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size of the nanocrystals was affected by the process
conditions, such as the freezing rate. However, it was not
clear during which stage of the process the solutes crystallized
and how the freezing rate caused its effect on the crystal size.
Since the mixture is thermodynamically unstable, the drug and
the matrix could crystallize (1) during freezing, (2) after freezing
ata temperature above the temperature of the maximally freeze-
concentrated fraction (Tg′), or (3) during drying. Knowledge on
when and how crystallization occurs can help to elucidate the
mechanisms through which parameters such as freezing rate
affect the ﬁnal size of the crystals. Crystallization processes can
be monitored with Raman spectroscopy. The effects of the
process conditions on the drug particle size couldbe elucidated if
the crystallization of both the solvents and the solutes could be
monitored during the freeze-drying process.
The aim of the study was to elucidate the mechanisms
that determine the size of the drug crystals formed during
freeze-drying. Thereto, in-line Raman spectroscopy was used
as process analytical tool. Since Raman spectroscopy is a fast,
non-invasive technique, it offers the opportunity to monitor
physical changes of the formulation during freeze-drying. One
of the advantages of Raman spectroscopy is that Raman
spectra show sharp peaks by which individual components
generally do not overlap each other. This makes it relatively
easy to determine which component crystallizes at which
stage during the process (19).
In this study, a Raman probe was placed immediately
above the sample in the freeze-drier (as described by De Beer
et al.( 20)). By using this in-line method, the crystallization of
the four components (a model drug, matrix, TBA, and water)
during the process could be monitored. The different stages
during the CCDF-process (freezing, increase in temperature,
and drying) were separated from each other and prolonged to
ensure that the complete phase changes during each stage
were measured. In addition, two process conditions, the
freezing rate and the temperature of the freeze-dryer shelf,
were varied. Monitoring the crystallization process yields
insight into the moment and length of the crystallization of
the different components, while varying the process condi-
tions reveals which factors inﬂuence the model drug crystal
size and therefore the dissolution rate. Fenoﬁbrate and
mannitol were used as the model drug and the matrix
material, respectively.
MATERIALS AND METHODS
Materials
Fenoﬁbrate and TBA were obtained from Sigma-Aldrich
Chemie B.V. Zwijndrecht, The Netherlands. Mannitol was
purchased fromVWRinternational (FontenaysousBois,France).
Methods
Preparation of the Crystalline Dispersions
Crystallized dispersions were prepared similar to the
method described previously (18). Brieﬂy, the drug, fenoﬁ-
brate, was dissolved in TBA (25 mg/ml) and the matrix
material, mannitol, in water (31 mg/ml). The solutions were
heated to approximately 60°C and 2.4 ml of the aqueous
solution was mixed with 1.6 ml of the TBA solution. After
mixing, the vials were frozen. Two freezing rates were used:
immediately freezing the vials on a pre-cooled (−50°C)
freeze-dryer shelf (cooling rate of the sample approximately
2.5°C/min); and freezing at 1°C/min by placing the vial on the
shelf at 20°C and cooling the shelf to −50°C at a rate of 1°C/min
(cooling rate of the sample approximately 0.8°C/min). In both
cases, the temperature of −50°C was maintained for 2 h. The
temperature of the shelf was then increased to either −25°C or
−15°C in 30 min and this temperature was maintained for
another 7 h. Next, sublimation of the solvents was initiated by
decreasing the pressure to 0.8–1.0 mbar in 20 min and the
samples were dried for 30 h (see Table I). The temperature of
the shelf was then gradually (2 h) raised to room temperature.
Finally, the freeze-dryer (Amsco-Finn Aqua GT4 freeze-dryer)
was emptied and the samples, having a drug load of 35% w/w,
were stored in a vacuum desiccator over silica gel for at least
1 day before further processing.
In-Line Raman Spectroscopy
A non-contact probe coupled to a RamanRxn1 spec-
trometer (Kaiser Optical Systems, Ann Arbor, Michigan,
USA) via a glass ﬁber optic cable, was placed immediately
above a vial inside the freeze-dryer. The spectrometer was
equipped with an air-cooled CCD detector (back-illuminated
deep depletion design). The laser wavelength was the 785-nm
line from a 785 Invictus NIR diode laser. Spectra were
collected every minute during freeze-drying and the exposure
time was 30 s. All spectra were recorded at a resolution of
4c m
−1 using a laser power of 400 mW. The HoloREACT
reaction analysis and proﬁling software package, the Matlab
Software package (version 6.5), and the Grams/AI-
PLSplusIQ software package (version 7.02) were used for
data-collection, -transfer, and -analysis. Spectra were
preprocessed by baseline correction (Pearson’s method).
Differential Scanning Calorimetry
Thedegreeofcrystallinity(deﬁnedastheratiobetweenthe
heat of fusion of the drug or carrier in the solid dispersion and
the heatoffusion of the drug orcarrieras receivedmultipliedby
the fraction drug or carrier in the mixture) of fenoﬁbrate and
mannitol in the crystallized dispersions was determined by
differential scanning calorimetry (DSC). Hermetically closed
aluminumpanswereﬁlledwith2–8mgofthesampleandheated
at 2°C/min, from −50 to 200°C in the scanning calorimeter
(Q2000, TA Instruments, Ghent, Belgium).
X-ray Powder Diffraction
X-ray powder diffraction (XRPD) was used to determine
the crystallinity and identify the polymorphic forms of both
solutes. Therefore a CuKα radiation with a wavelength of
1.5405 Å at 40 kV and 40 mA from an X'Pert PRO MPD
diffractometer (PANalytical, Almelo, The Netherlands) was
used. The sample powders were placed on a zero-background
silicon holder (diameter, 32 mm; thickness, 2 mm) and
scanned from 4–60° 2θ with a step size of 0.008° and a time
per step of 35 s.
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The obtained powders were compressed to 9-mm
tablets of 100 mg on a ESH compaction apparatus (Hydro
Mooi, Appingedam, The Netherlands). The compaction
rate was 5 kN/s to a maximum compaction load of 5 kN.
The tablets were stored in a vacuum desiccator over silica
gel at room temperature for at least 1 day before further
processing.
Dissolution
The dissolution rate of fenoﬁbrate from these tablets was
tested in a USP dissolution apparatus II, Rowa Techniek.
Dissolution was performed in 1 L of a 0.5% w/v sodium
dodecyl sulfate solution at 37°C; the paddle speed was
100 rpm. The concentration of fenoﬁbrate was measured
spectrophotometrically (UV–VIS spectrophotometer UV-
1601, Shimadzu) at a wavelength of 290 nm.
RESULTS
Physicochemical Characterization of the Dispersions
The physical properties of the obtained freeze-dried
product were determined by both DSC and XRPD. The
DSC thermograms of all four dispersions showed melting
peaks corresponding to crystalline fenoﬁbrate and crystalline
mannitol. Mannitol exists as three anhydrous polymorphs
whose melting points differ only slightly (166.5, 166, and 155°C
for the α-, β-, and δ-polymorphs, respectively (21)). Therefore,
DSC is not the most suitable method to identify which
polymorph has been formed. The XRPD patterns showed that
all samples contained only the δ-polymorph (Fig. 1).
Although the pure mannitol as received did not consist of
δ-mannitol, DSC can be used to determine the degree of
crystallinity of mannitol since the melting enthalpies of α-,
β-, and δ-mannitol are also similar (21). Fenoﬁbrate and
mannitol in all four dispersions were highly crystalline and
had a similar degree of crystallinity (96–102% for fenoﬁ-
brate and 92–95% for mannitol; Table II).
In-Line Raman Spectroscopy
Each crystalline component had a characteristic peak
that did not overlap with characteristic peaks of any of the
other components (Fig. 2). The characteristic peak used for
Table I. Description of the Process and its Variables to Crystallize and Freeze-Dry the Water/TBA Mixtures
Step Temperature (°C) Length of step (h) Pressure (mBar)
1. Freezing Variable 1 1000
−50 2 1,000
2. Ramping to Tc
a Variable 2 0.5 1,000
3. Crystallization Variable 2 7 1,000
4. Drying Variable 2 30 0.8–1.0
5. Ramping to Tend 20 2 0.8–1.0
20 1 0.8–1.0
6. Emptying 20 - 1000
Process Variable 1: freezing rate Variable 2: Tc
a
1. (Slow; −25°C) From 20 to −50°C at 1°C/min −25°C
2. (Slow; −15°C) From 20 to −50°C at 1°C/min −15°C
3. (Fast; −25°C) Vial on pre-cooled shelf (−50°C); −25°C
4. (Fast; −15°C) Vial on pre-cooled shelf (−50°C) −15°C
aTc crystallization temperature
Fig. 1. a X-ray diffraction patterns of fenoﬁbrate as received, α-, β-,
and δ-mannitol and b the controlled crystallized dispersions contain-
ing 35% w/w fenoﬁbrate in mannitol (patterns of the mannitol
polymorphs were taken from the ICDD-library)
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−1,for mannitolat865–895cm
−1,
forTBAat725–763cm
−1,andforwaterat208–226cm
−1(22–24).
Since these peaks can be clearly distinguished from each other, it
is possible to use in-line Raman spectroscopy to monitor the
crystallization of the individual components. To determine when
crystallization of fenoﬁbrate, δ-mannitol, and water started and
ended, the peak intensity of each individual characteristic peak
was determined. An increase in peak intensity indicates the start
of crystallization. The peak intensity of the TBA peak cannot be
used for the determination of the start and end of the TBA
crystallization, since liquid TBA already shows a peak with a
high intensity. Therefore, the width of the TBA peak was used to
determine the crystallization of TBA. A narrowing of the peak
indicates the start of the crystallization of TBA (25).
Furthermore, it should be mentioned that Raman spectroscopy
only allows to measure the surface of the sample.
The intensity of the water peak increased and the width
of the TBA peak decreased during the freezing stage of
process 1 (Fig. 3), corresponding to the crystallization of the
solvents. The intensity of the fenoﬁbrate peak decreased
slightly due to the decrease in temperature and the peak of
crystalline mannitol was not detected during this stage of the
CCDF-process. Thus, only the solvents and not the solutes
crystallized during the freezing stage. After approximately
80 min, the intensity of the solvent peaks did not change
anymore, indicating that almost all solvent had crystallized.
At this point during the CCDF-process, the system consisted
of crystalline water (ice), crystalline TBA, and a vitriﬁed
freeze-concentrated solution of fenoﬁbrate and mannitol in a
mixture of water and TBA.
After the temperature was increased to −25°C, the
intensity of the peaks corresponding to both fenoﬁbrate and
mannitol increased. Indicating that the solutes crystallized at
this stage. Since the intensities did not change any further
after approximately 460 and 480 min for fenoﬁbrate and
mannitol, respectively (Table III), which was well before the
vacuum was applied (after 640 min), these data show that
fenoﬁbrate and mannitol crystallized completely before the
drying step started. After 650 min the width of the TBA peak
increased and the intensity of the water peak decreased,
indicating that sublimation started immediately after the
pressure was decreased. Due to the sublimation of the solvents,
the concentration of the solutes, and therefore the intensities of
thesolutepeaks,increased.After1,144and980minthepeaksof
TBA and water, respectively, disappeared. Since only the
surface of the sample can be measured by Raman spectroscopy,
this indicates that the top of the sample was dried in
approximately 8.5 h. To end with a completely dry crystalline
dispersion, the total drying time used was 30 h.
The solutes and solvents of the other three processes
crystallized at the same stages of the freeze-drying process as
found for process 1 (Table III; note that step 2 of processes 3
and 4 start 70 min earlier than step 2 of process 1 and 2, due
to the different freezing rate). The solvent crystallized upon
cooling, while crystallization of the solutes was not observed
at this stage. The solutes crystallized after the temperature
had been increased to −25°C (processes 1 and 3) or −15°C
Table II. Degree of Crystallinity of both Drug and Matrix (Mean±
Standard Deviation; n=3)
Process
Degree of crystallinity
Fenoﬁbrate Mannitol
1. (Slow; −25°C) 102.3±0.8 91.9±0.2
2. (Slow; −15°C) 99.5±0.6 92.5±0.6
3. (Fast; −25°C) 96.4±2.2 95.1±1.2
4. (Fast; −15°C) 100.2±1.2 91.5±2.1
Fig. 2. Raman spectrum of the sample during freeze-drying it
according to process 1 after 500 min. The peaks used to determine
the intensities of the individual components are encircled
Fig. 3. The intensities of fenoﬁbrate (1,580–1,610 cm
−1), mannitol
(865–895 cm
−1), and water (208–226 cm
−1) peaks and the peak width
of TBA (725–763 cm
−1) during the ﬁrst 1,000 min of process 1.
During this process the freeze-drier shelf was cooled during the ﬁrst
70 min from 20°C to −50°C, then the temperature was kept constant
at −50°C for 120 min, then the temperature of the freeze-drier shelf
was increased to −25°C in 30 min and kept constant for 420 min.
Finally, the pressure was decreased to 0.8–1.0 mBar to dry the
samples
572 de Waard et al.(processes 2 and 4). Even if the mixture was cooled at a rate
of at least 1°C/min, the solutes did not crystallize during
freezing, but only after the temperature was increased. Since
the intensity of the solute peaks reached a constant value
before the vacuum was applied, the solutes indeed crystal-
lized only during the time between freezing and drying.
Dissolution
As expected from earlier studies (18,26), the dissolution
rate of samples that were made by rapid freezing (vials placed
on a pre-cooled freeze-dryer shelf) was higher than the
dissolution rate of samples that were frozen more slowly
(at 1°C/min; see Fig. 4). Furthermore, a relatively low shelf
temperature during the crystallization stage (−25°C) resulted
in faster dissolution than a relatively high shelf temperature
(−15°C). Between the samples that were crystallized at a
relatively low temperature, the effect of the freezing rate on
the dissolution behavior is negligible, indicating that crystal-
lization at a lower temperature could diminish the effect of
the freezing rate. Since all samples had a similar degree of
crystallinity and consisted of the same polymorphic forms,
differences in dissolution rate can be attributed to differences
in crystal size (18,26). Thus, both the rate of freezing and the
temperature at which crystallization occurs inﬂuence the ﬁnal
particle size. Based on the dissolution data, we conclude that
a higher freezing rate and a lower temperature at which the
solutes crystallized, resulted in smaller drug crystals.
DISCUSSION
In this study, we clearly elucidated the mechanism of
crystallization during the CCDF-process. The in-line Raman
spectroscopy measurements showed that the solvents and the
solutes crystallized at different steps during the CCDF-
process. During the freezing step, the solvents crystallize.
Due to the crystallization of the solvents, the remaining
solution becomes more concentrated. Since the remaining
solution (containing fenoﬁbrate, mannitol, TBA, and water)
is thermodynamically unstable, the solutes can start to
crystallize as well. However, if the freezing occurs rapidly,
and if the system is cooled to a temperature well below the
Tg′, the mobility is strongly reduced and a rigid glass is formed.
Due to the strongly reduced mobility neither the solvents nor
the solutes can crystallize in the freeze-concentrated fraction.
The in-line Raman data show that the solutes did not crystallize
at the freezing stage of the CCDF-process. Thus, the freezing
rate (even at 1°C/min) is apparently fast enough to prevent
crystallization of the solutes during freezing and the reached
temperature of −50°C is well below the Tg′.
After step 2, when the temperature was increased to
either −25°C or −15°C, the solutes crystallized and the
crystallization was ﬁnished before the next step, drying, was
started. The Tg′ of the solutes could not be properly
measured in this complex system by DSC (data not shown),
but since the solutes crystallized at these temperatures, the
temperature of the system was apparently above the Tg′.A t
temperatures below the Tg′, the freeze-concentrated fraction
is glassy and the solutes cannot crystallize.
Although the solutes crystallized solely during the step
after the freezing step, not only the crystallization temperature,
but also the freezing rate determined the particle size of the
powder. Therefore, we conclude that two phenomena play a
role in the formation and growth of the crystals during CCDF.
The ﬁrst process variable that determines the ﬁnal crystal
size was the freezing rate. A higher freezing rate resulted in
smaller crystals. This effect was already shown in an earlier
study, in which we also speculated about different mecha-
nisms that could determine the drug crystal size (18). Since
we have shown in this study that both the drug and the matrix
Table III. Summary of the Average Time at which the Crystallization of Each Individual Component Starts and Ends
Crystallization times (min)
Process 1 Process 2 Process 3 Process 4
Start End Start End Start End Start End
Fenoﬁbrate 291 461 273 353 243 439 207 307
Mannitol 237 480 231 379 222 475 199 314
TBA 59 75 44 67 15 30 14 25
Water 71 80 63 68 19 33 21 26
Fig. 4. Dissolution proﬁles of tablets composed of a physical mixture
( ) and controlled crystallized dispersions of 35% w/w fenoﬁbrate in
mannitol. Controlled crystallized dispersions were prepared by slow
freezing (closed symbols) or fast freezing (open symbols) and a low
(−25°C) crystallization temperature (circles)o rah i g h( −15°C)
crystallization temperature (triangles). Process 1 corresponds to (●),
process 2 corresponds to (▲), process 3 corresponds to (○), and
process 4 corresponds to (△)( n=3–6; mean±standard deviation)
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solvent crystals determines the ﬁnal solute crystal size. A
higher freezing rate results in smaller solvent crystals (27) and
consequently smaller interstitial spaces, containing the freeze-
concentrated fraction, between the solvent crystals. Since the
solutes crystallized in the freeze-concentrated fraction, the
size of the interstitial spaces limits the ﬁnal size of the solute
crystals. Thus, a high freezing rate results in smaller solvent
crystals and therefore smaller interstitial spaces and conse-
quently smaller solute crystals.
The second process variable that determines the crystal
size is the shelf temperature. We found that a lower shelf
temperature during crystallization (−25°C vs. −15°C) resulted
in smaller crystals. At a lower shelf temperature, the degree
of supersaturation is higher, resulting in a higher nucleation
rate (28). Since the formation of new nuclei and crystal
growth are two competing processes (29), a higher nucleation
rate results in more nuclei and consequently in smaller
crystals. Thus, although the size of the interstitial spaces
(controlled by the freezing rate) determines the maximum
particle size, the crystal size is also determined by the balance
between the formation of new nuclei and crystal growth
(controlled by the shelf temperature).
CONCLUSION
In this study, we revealed during which stages of the
CCDF-process the solvents as well as the solutes crystallized.
Based on this, we identiﬁed the critical steps for crystal
formation for the model drug fenoﬁbrate during freeze-
drying. CCDF consists of three successive steps: freezing,
increasing the temperature, and drying. The in-line Raman
measurements showed that the ﬁrst two steps, the freezing
step and the crystallization step are critical steps that
determine the ﬁnal size of the fenoﬁbrate crystals. When the
mixture was frozen more rapidly, the interstitial spaces
between the solvent crystals are smaller and because the size
of the solute crystals is limited by the size of the interstitial
spaces, smaller fenoﬁbrate crystals are formed. When the
solutes crystallize at a lower shelf temperature, the degree of
supersaturation in the freeze-concentrated fraction is higher.
A higher degree of supersaturation (as caused by lower
crystallization temperatures) results in a higher nucleation
rate and consequently more and therefore smaller fenoﬁbrate
crystals are formed. The combination of a high freezing rate
and a relative low crystallization temperature results in the
smallest fenoﬁbrate crystals and consequently a higher
dissolution rate. Furthermore, these results show that the
fenoﬁbrate crystal size can be controlled by choosing the
appropriate freezing rate and shelf temperature. Further
studies are necessary to prove whether the critical steps as
deﬁned in this study and the mechanism of crystal formation
are generally applicable to other lipophilic drugs.
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